Impact of HIV status on outcome of infectious complications in intravenous drug users

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 4, 2009, Pages 506-507

  Mertz, Dominik ^a   Viktorin, Nina ^a   Wolbers, Marcel ^b   Flückiger, Ursula ^a   Battegay, Manuel ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LETTER; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT;

HIV SEROPOSITIVITY; HUMANS; LENGTH OF STAY; PATIENT READMISSION; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 68049127846     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181acb724     Document Type: Letter

References (3)

1. Hsieh YH, Rothman RE, Bartlett JG, et al. HIV seropositivity predicts longer duration of stay and rehospitalization among nonbacteremic febrile injection drug users with skin and soft tissue infections. J Acquir Immune Defic Syndr. 2008;49:447-450.
2. Mertz D, Viktorin N, Wolbers M, et al. Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis. BMC Infect Dis. 2008;8:42. (Pubitemid 351575087)
3. Mertz D, Khanlari B, Viktorin N, et al. Less than 28 days of intravenous antibiotic treatment is sufficient for suppurative thrombophlebitis in injection drug users. Clin Infect Dis. 2008;46:741-744. (Pubitemid 351321559)